Investment
Features
FeesSafety
Academy
More
Pluang+

Viking Therapeutics starts Phase 3 trials for oral VK2735 to treat obesity and type 2 diabetes.

Company Fundamentals
14 Oct 2026
PRNewsWire
View Source
Bullish
Viking Therapeutics starts Phase 3 trials for oral VK2735 to treat obesity and type 2 diabetes.

Viking Therapeutics has launched the SUNRISE Phase 3 clinical trials to evaluate oral VK2735, a dual GLP-1/GIP receptor agonist, in obese adults with and without type 2 diabetes. The trials will assess the drug's efficacy and safety over 68 weeks, focusing on body weight reduction compared to placebo. Positive Phase 2 results showed significant weight loss and good tolerability, supporting the advancement of this oral therapy as a convenient treatment option. Viking also continues Phase 3 trials for a subcutaneous form of VK2735, aiming to offer flexible treatment choices for long-term obesity management.

Viking Therapeutics' VK2735 clinical program is the subject, with Pluang market data offering context. Of 150 Health-sector US stocks on Pluang, 103 rose and 40 fell as of Oct 14, 2026 18:11 WIB. Notable movers include BNGO at USD 1.39 (+1.84%, 98% Sell), AZN at USD 158.62 (+1.80%, 58% Sell), and NVS at USD 144.94 (+1.78%, 82% Sell).

More News

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global wins Best AI Solution for Software Development at 2026 AI in Capital Markets Awards

Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...

Others
Bullish
20 minutes ago
nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz named Accelerator in 2026 Nucleus Research TMS Value Matrix for last-mile delivery tech

nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...

Market News
Bullish
20 minutes ago
ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML reports strong Q3 2026 EPS of $14.65 on high chip equipment demand despite slight revenue miss.

ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...

Company Fundamentals
Bullish
1 hour ago
Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab Q3 earnings expected to rise on strong trading and asset management revenue.

Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...

Company Fundamentals
Bullish
1 hour ago
TSOs prioritize software investments to boost grid security and capacity amid rising demand

TSOs prioritize software investments to boost grid security and capacity amid rising demand

Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App